Prospective Double-Blind PBO-Controlled Combined Crossover Randomized Withdrawal Study of Latiglutenase in T1D/CD Pts
Condition: Celiac Disease Interventions: Drug: Latiglutenase; Drug: Placebo Sponsors: Immunogenics, LLC; National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Celiac Disease | Coeliac Disease | Diabetes | Endocrinology | Research | Study | Urology & Nephrology